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Approaches to vaccine-based immunotherapy of human cancer may ultimately require targets that are both tumour-specific and
immunogenic. In order to generate specific antitumour immune responses to lung cancer, we have sought lung cancer-specific
proteins that can be targeted for adjuvant vaccine therapy. By using a combination of cDNA subtraction and microarray analysis, we
previously reported the identification of an RNA-binding protein within the KOC family, L523S, to be overexpressed in squamous cell
cancers of the lung. We show here that L523S exhibits significant potential for vaccine immunotherapy of lung cancer. As an
oncofetal protein, L523S is normally expressed in early embryonic tissues, yet it is re-expressed in a high percentage of nonsmall cell
lung carcinoma. The specificity of L523S expression in lung cancer was demonstrated by both mRNA and protein measurements
using real-time PCR, Western blot, and immunohistochemistry analyses. Furthermore, we show that immunological tolerance of
L523S is naturally broken in lung cancer patients, as evidenced by detectable antibody responses to recombinant L523S protein in
eight of 17 lung pleural effusions from lung cancer patients. Collectively, our studies suggest that L523S may be an important marker
of malignant progression in human lung cancer, and further suggest that treatment approaches based on L523S as an immunogenic
target are worthy of pursuit.
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Among all human cancers, carcinoma of the lung has the highest
mortality rate and is the leading cause of all cancer deaths.
Although the majority of patients diagnosed with most histological
types of lung cancer respond initially to conventional therapies,
they often relapse within a relative short period of time, leaving no
significant improvement in survival. Immunotherapy of lung
cancer has been actively pursued in recent years (Bunn, 1999).
However, randomised trials using nonspecific immune stimulants
such as interferon have failed to show significant effects on lung
cancer survival (Jett et al, 1994; van Zandwijk et al, 1997). Most
pioneering studies of targeted cancer vaccine therapy have focused
on melanoma, which is the most immunogenic solid tumour and
has abundantly expressed melanoma-specific gene products.
Clinical trials using antigens that are specifically expressed or
overexpressed in melanomas are currently under investigation and
these vaccines are targeted for humoral (B cell) and/or cellular
responses (cytotoxic T cells) (Robbins and Kawakami, 1996;
Brinckerhoff et al, 2000). The success of therapeutic cancer
vaccines may ultimately rely on the identification of immunogenic
antigens that are overexpressed in tumours relative to essential
normal tissues.
In an effort to identify tumour antigens that can be targeted for
specific immunotherapy, we used a high throughput method for
identifying genes overexpressed in lung squamous cell carcinoma
(LSCC) (Wang et al, 2000). Among 17 candidates found to be
overexpressed in LSCC, we described one candidate, L523S, which
has now risen to lead status. L523S was initially identified as a gene
encoding a KOC RNA-binding protein that is overexpressed in
pancreatic cancer (Mueller-Pillasch et al, 1997). Also known as
IMP-3, L523S binds and regulates IGF-II transcripts during
embryogenesis (Nielsen et al, 1999). In this report, we describe
additional evaluation of L523S as a lung cancer vaccine candidate.
MATERIALS AND METHODS
Tissue, lung pleural effusion, and RNA sources
Tumour and normal tissues used in this study were obtained from
Cooperative Human Tissue Network (CHTN), National Disease
Research Interchange (NDRI), and Roswell Park Cancer Center.
Other normal tissues were purchased from Clontech (Palo Alto,
CA, USA) and Invitrogen (Carlsbad, CA, USA). Lung pleural
effusions used in this study come from advanced stage IV patients
with nonsmall cell lung carcinoma cancers (NSCLC). Nine of 11
lung squamous cell carcinoma (LSCC) samples, and 11 of 14 lung
adenocarcinoma samples used for IHC analysis (Table 1) are from
National Kinki-Chuo Hospital, Osaka, Japan. Among these
samples, 12 are stage I tumours, four are stage II tumours, and
four are stage III tumours.
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As described previously in detail (Wang et al, 2000), L523S was
identified as a gene overexpressed in LSCC using 23 pairs of cDNA
probes synthesised from mRNA of lung tumour, normal lung, and
other tumour and normal tissues. The expression profile for L523S
was illustrated in pseudocolours representing pairs of Cy3 and Cy5
hybridisation signals, white being the highest and black being the
lowest (Figure 1A).
Quantitative real-time PCR analysis
To compare the relative level of gene expression in multiple tissue
samples, a panel of 36–66 cDNA samples was constructed using
total RNA extracted from tissues and/or cell line(s), and real-time
PCR was performed using gene-specific primers to quantify the
copy number in each cDNA sample. Each cDNA sample was tested
in duplicate and the final real-time PCR result was reported as
an average of copy number of a gene of interest normalised
against copy number of internal actin gene in each cDNA sample.
Figure 1B shows as extended LSCC panel with various stages
of tumours. Details of cDNA sources are also denoted.
Specific primers used for real-time analysis are L523S-FW (50
CATGGACTGGCTTTCTGGTTG 30) and L523S-RV (50CTGA-
GAAAAGCTCTGGCCTTAAAC30). All real-time PCR reactions
were run on a GeneAmp 5700 Detector using SYBR Green I dye
(Perkin Elmer/Applied Biosystems Division, Foster City, CA, USA).
Conventional RT–PCR analysis
Normalised mouse cDNAs from heart, brain, spleen, lung, liver,
skeletal muscle, kidney, testis, 7, 11, 15, and 17-day embryo tissues
were purchased through Clontech (Palo Alto, CA, USA). Each
human cDNA used is also normalised by internal actin copy
numbers. L523S universal primers (forward: 50 ATGAATCTT-
CAAGCACATTTA 30, and reverse: 50 TCTCATCAGGTGTCTGGT-
CAC 30) are 100% conserved between human L523S cDNA and its
mouse homologue. Standard PCR analysis was performed (35
cycles).
L523S protein expression and polyclonal antibody
generation
Escherchia coli recombinant L523S protein was expressed in pPDM
His, a modified pET28 vector (Novagen Inc., Madison WI, USA).
Amino acid 2–580 of L523S was expressed in frame with an
N-terminal His tag (MQHHHHHH). L523S protein was purified
through nickel-affinity chromatography and ion-exchange
Table 1 IHC analysis of L523S
Tissues Staining Comments
Squamous tumour Positive 11 out of 12
Adenocarcinoma Positive 12 out of 14
Adrenal Negative
Artery – endothelium Negative
Urinary Bladder Negative
Blood (bone marrow) Negative
Brain (basal ganglia) Negative
Brain (cortex) Negative
Breast Negative
Colon Positive (1 out of two) Mild cytoplasmic staining of colonic epithelial cells
Oesophagus Negative
Fallopian tube Positive Mild cytoplasmic staining of epithelium
Gall bladder Positive Mild cytoplasmic staining of epithelium
Heart Negative
Kidney Negative
Liver Negative
Lung Negative (zero out of six)
Lumph node Negative
Ovary Positive Follicular epithelium marginally label; otherwise negative
Pancreas Negative
Parathyroid Negative
Pituitary Positive Mild cytoplasmic staining of cells in the pars anterior
Parathyroid Negative
Pituitary Positive Mild cytoplasmic staining of cells in the pars anterior
Placenta Positive Syncytial trophoblasts of terminal villi
Prostate Negative
Skeletal muscle Negative
Skin Negative
Small bowel Negative
Spinal cord Negative
Spleen Negative
Stomach Negative
Testes Negative
Thymus Negative
Thyroid Negative
Ureter Negative
Uterus Negative
Bronchus Positive Mild staining of columnar, ciliated epithelium
Trachea Negative Epithelium not present; otherwise negative
Tonsil Positive Staining of some germinal control cells/epithelial crypts
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L523S protein was subjected to N-terminal sequencing analysis to
confirm its identity. Rabbit anti-L523S polyclonal antisera were
generated and affinity purified. Anti-L523S F(ab) fragment of IgG
molecule was generated by cleavage with 0.5mgml
 1 papain at
371C for 2h followed by protein A removal of uncleaved and
cleaved Fc region and dialysis in PBS.
Western blot and immunohistochemistry analysis
Total cellular lysate was prepared by homogenising small pieces of
snap-frozen tissues in three-volume lysis buffer (250mM sucrose,
20mM HEPES, pH7.5, and 1mM EDTA), followed by 5min
centrifugation with 5000r.p.m. at 41C. 10mg of total protein lysate
was loaded in each lane on two SDS–PAGE gels with 10ng
recombinant L523S used for positive control. After electrophoresis,
one gel was stained with Commassie blue, and the other was
electroblotted onto a nitrocellular membrane followed by primary
antibody (1:10000 dilution of anti-L523S polyclonal antibody)
and secondary antibody (1:5000 dilution of HRP-conjugated goat
anti-rabbit) incubation. The blot was developed by ECL reagents.
Immunohistochemsitry analysis was performed with affinity-
purified anti-L523S polyclonal antibody. In all cases, 4mm sections
of formalin-fixed, paraffin-embedded tissues were used. Tissues
were subjected to 20min steam-heat-induced epitope retrieval in
presence of 10mM sodium citrate buffer (pH 5.6–6.0) before being
stained with either 1mgml
 1 of IgG or 4.0mgml
 1 F(ab) anti-L523S
rabbit polyclonal antibody. Tissues were then incubated with a
biotinylated anti-rabbit secondary antibody. After endogenous
peroxidase blocking, the avidin–biotin complex/HRP (ABC/HRP)
was used along with DAB chromogen to visualise protein
expression.
ELISA and Western blot analysis using lung pleural
effusion from lung cancer patients
ELISA was performed using recombinant L523S protein with lung
pleural effusion fluids from lung cancer patients and sera from
normal donors following a standard ELISA protocol. Briefly, a 96-
well microtitre plate was coated with 350ngwell
 1 L523S protein
overnight at 41C and blocked by 10% nonfat dry milk in PBS for
3h at room temperature. Pleural fluid titres from 17 NSCLC
patients as well as 48 sera from normal donors were tested at 1:30,
1:100, 1:300, and 1:1000 dilutions, in PBS with 5% goat sera and
5% nonfat dry milk for 3h at room temperature. After 30min
secondary antibody incubation with 1:8000 of HRP-conjugated
donkey anti-human IgG+IgM (Jackson ImmunoResearch Lab.,
West Grove, PA, USA), the plate was developed by ortho-
phenylendiamine and hydroperoxide. The Western blot analysis
was performed as described above using 1mg recombinant L523S
and 1:30 to 1:300 dilutions of patient pleural effusions.
RESULTS
L523S expression in lung cancer
Microarray analysis of L523S using 23 pairs of cDNA probes
synthesised from polyA+RNA of tumour and normal tissues
showed elevated L523S expression in four of four LSCC samples
(pooled, 9681T, 9688T, and 96A) with little or no expression
detected in normal tissues (Figure 1A). Two of three lung
adenocarcinoma cDNA samples also showed increased expression
of L523S, but at a lower level (pleural effusion 86–52 and 8009T).
The expression profile of L523S observed through microarray
analysis was confirmed by real-time PCR analysis using cDNA
panels comprised of samples from both LSCC and lung
adenocarcinoma (data not shown). In order to determine the
frequency of L523S expression in LSCC and adenocarcinoma, as
well as to assess potential correlation of L523S expression with
stages of each histological type of lung cancer, we examined the
L523S expression in an extended cDNA panel using real-time PCR.
The LSCC panel contained 26 cDNA samples derived from stage I
to stage IV tumours, including two head and neck samples, and the
lung adenocarcinoma panel comprised 25 cDNAs derived from
adenocarcinoma of different stages. As shown in Figure 1B, L523S
is overexpressed in 21 of 26 squamous cell carcinoma samples and
at all tumour stages. L523S expression in lung adenocarcinoma
appeared to be more heterogeneous, again with no correlation with
disease stage, but in a lower overall proportion of tumours (seven
of 26 lung adenocarcinoma samples, data not shown). Expression
of L523S in 34 normal tissues was found to be minimal when
examined on normal tissue cDNA panels by real-time PCR
(Figure 1B).
L523S is a highly conserved oncofetal protein
Oncofetal protein are by definition proteins that are normally
expressed only during embryonic development and then re-
expressed in cancers. Some oncofetal protein are also expressed in
Cy3 Cy5
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Figure 1 (A) Microarray analysis of L523S. Pseudocolour images of
hybridisation intensities (white being the strongest and black being the
weakest) were shown between 23 pairs of probes in Cy3 and Cy5 channels
as indicated. (B) Real-time PCR analysis of L523S in NSCLC using an
extended panel of 66 cDNA samples for LSCC. Overexpression is defined
as X10-fold expression compared with average expression in all normal
tissues, or Xthree-fold expression compared with highest expression in
normal tissues. Overexpression of L523S was detected in 21 of 26
squamous tumours with 24 being LSCC. Expression of L523S was not
associated with stages of the disease. (Figure continued on next page.)
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an L523S mouse homologue (96% identical at the protein level) is
ubiquitously expressed during early stages of mouse embryogen-
esis (Mueller-Pillasch et al, 1999), indicating an important role for
L523S protein during early stages of embryonic development.
Since human and mouse L523S homologues are also highly
conserved at the cDNA level (92% identical), we investigated
whether L523S expression in lung cancer is at a level similar to that
of expression during embryogenesis. Using primers that recognise
both human and mouse L523S transcripts, we show by PCR
analysis that L523S, consistent with the definition of an oncofetal
antigen, is expressed in lung cancers (Figure 2, lanes
2–5) and early mouse embryos and mouse adult testis (Figure 2,
lanes 19–23). In contrast, we found little or no expression detected
in normal adult tissues of human (Figure 2, lanes 6–11) or mouse
(Figure 2, lanes 12–18).
L523S protein is localised in the cytoplasm of lung cancer
cells
Western blot analysis using affinity-purified L523S polyclonal
antibodies revealed that the L523S protein was present in lung
cancer samples. By using whole cell lysate extracted from tissues of
lung cancer and normal adult tissues, L523S protein was detected
in a large cell carcinoma and three LSCC samples (Figure 3A, lanes
2–5). A weaker L523S signal was also detected in a placenta tissue
sample (Figure 3A, lane 13).
Immunohistochemistry (IHC) analysis demonstrated that L523S
is present homogeneously in the cytoplasm of lung cancer cells,
both in squamous cell carcinoma (Figure 4A) and in adenocarci-
noma (Figure 4B). As shown in Figure 4C, L523S protein was only
detected in the tumour portion of the adenocarcinoma tissue
section, not in adjacent normal lung tissue, suggesting that its
expression is specifically associated with malignant cells. The
results of IHC analysis using an extensive panel of lung cancer and
normal tissues are summarised in Table 1. In total, 90% of LSCC
and adenocarcinoma scored positive for L523S immunoreactivity.
Although real-time PCR analysis showed that L523S mRNA levels
vary in lung adenocarcinoma samples (data not shown), the IHC
analysis clearly demonstrated that L523S protein is present in a
high percentage of lung adenocarcinoma. Consistent with mRNA
expression profiles, L523S immunoreactivity was not found in the
majority of normal adult tissues; however, light staining was
detected in a few normal epithelial cell types including fallopian
tube, gall bladder and normal bronchiolar epithelial cells (Table 1
and Figure 4D). Since the faint immunoreactivity observed in
normal epithelial cells might have resulted from nonspecific
binding of the Fc region of the IgG molecule, we performed IHC
analysis using purified F(ab) fragment of the IgG molecules
(Figure 4E–H). Under similar staining conditions, immunoreac-
tivity of L523S in normal bronchiolar epithelial cells was greatly
diminished (Figure 4G) with no apparent loss in signals for L523S
in two LSCC (Figure 4E, F), although the background under
previous condition is slightly higher. Nonetheless, L523S protein is
180
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Figure 1 Continued.
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cytoplasm of cancerous cells.
Antibody responses to L523S in lung cancer patients
To test whether L523S protein is immunogenic in lung cancer
patients, an ELISA was performed using recombinant L523S
protein to test for the presence of antibody responses in lung
pleural effusions from 17 patients (Table 2) (Rohrer et al, 1999;
Vollmer et al, 1999). Eight pleural effusions from lung cancer
patients gave positive signals (4two-fold signals in at least two
different titres compared with normal sera of 48 donors). These
positive signals are significant, as the immunoreactivity could not
be abolished by using E. coli protein lysates as competitors. Strong
antibody titres were observed in eight patients with no positive
signals detected in the sera of 48 normal donors (Table 2).
Although antibody titre in individual lung pleural effusions was
variable, the specificity of antibody response in each patient was
confirmed by Western blot analysis. Representative Western blot
analysis of lung pleural effusion antibody responses in two positive
and one negative patient is shown in Figure 5. L523S-specific
antibody reactivity was present in patient pleural effusion #12 and
#15 but not #3 (Table 2 and Figure 5). Other studies performed by
us (R Houghton and DH Persing, and others) have shown that sera
from patients with lung and other malignancies show reactivity to
L523S (unpublished observations).
DISCUSSION
In this report, we show that L523S is an oncofetal protein and is
overexpressed in lung squamous and adenocarcinoma tumours.
L523S is expressed in 80–90% of LSCC by mRNA measurements as
well as by IHC analysis. In addition, L523S is also expressed in a
significant majority of lung adenocarcinoma, making it an
attractive therapeutic target with broad coverage in NSCLC.
Similar to other ‘cancer antigens’ such as NY-ESO-1 (Jager et al,
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Figure 2 L523S is overexpressed in tumour and embryonic tissues. RT–PCR analysis of L523S expression in human tissues (lanes 2–11) and its
homologue in mouse tissues (lanes 12–23) was carried out under the same condition in a single experiment. Human cDNA was normalised by internal actin
at cycle numbers 20–22, and mouse cDNA was prenormalised by the manufacturer (Clontech, Palo Alto, CA, USA). Primers were designed to have 100%
identity to both human and mouse L523S cDNA sequences (see Materials and Methods for detail).
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Figure 3 Western blot analysis revealed a 70kDa L523S protein in one
large cell carcinoma and three LSCC tissues (A). This 70kDa protein was
not detected in any other normal tissues except for a weaker signal in the
placenta tissue. Notice that there was a lower molecular weight protein
present in normal kidney and placenta tissues, and a 20kDa band was also
visible in the liver sample. Parallel gel with total proteins from cell lysate was
stained with Commassie (B).
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appears to be naturally overcome in a significant proportion of
lung cancer patients, suggesting a role for antigen-presenting cells,
helper cells, and B cells in facilitating such responses. Since
expression of L523S appears to be extremely limited in adult
normal tissues, humoral and/or cellular immune responses
directed against L523S are likely to be tumour specific and
perhaps less likely to trigger autoimmune responses. Indeed,
limited normal tissue expression of L523S may account for the
Figure 4 Immunohistochemistry analysis of L523S using affinity-purified whole IgG molecules (A–D) and F(ab) fragments (E–H). Illustrated here are
results of IHC staining on tissue sections of LSCC (A, E, F), lung adenocarcinoma (B), lung adenocarcinoma with adjacent normal lung tissue (C), and
normal tissues of lung (D, H). Homogeneous cytoplasm staining was observed in both squamous and adenocarcinoma samples (A–C, E, F). Arrows point
to bronchiole epithelial cells that were lightly stained with whole IgG molecules (D), but not with F(ab) fragments (G).
165 kDa
105 kDa
76 kDa
46 kDa
37 kDa
28 kDa
20 kDa
14 kDa
1          2 1′        2′           3′
Stain Blot
A B
MW
LPE # 3
LPE # 12
LPE # 15
Recomb.L523S-p
Figure 5 Western blot analysis of immunoreactivity of lung cancer
patient antibody to L523S. (A) Silver staining of recombinant L523S protein
purified through nickel chromatography (lane 2). The arrow in (A) points
to L523S protein confirmed by N-terminal sequencing analysis. (B) L523S
recombinant protein was probed with lung pleural effusion from patient #3
(lane 10), #12 (lane 20), and #15 (lane 30). Notice that stronger antibody
titre in #12 detected by ELISA analysis (Table 2) also has increased
immunoreactivity to L523S protein by Western blot analysis.
Table 2 Antibody responses to L523S in lung cancer patients
Lung pleural
effusion from patients
Responses
to BSA
Responses
to L523S
1   
2   
3   
4   ++
5   ++
6   
7   +++
8   ++
9   ++
10   +++
11   
12   +++
13   
14   
15   ++
16   
17   
48 sera from nomal donors  
The data are derived from ELISA. The specificity of the antibody response in each
ELISA-positive sample was also confirmed by Western blot analysis. ‘++’ Indicates
that Western blot result was obtained with more than 30-fold dilution of LPE,
whereas ‘+++’ denotes immunoreactivity by Western blot with more than 300-fold
dilution of the LPE samples.
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of 17 pleural effusion samples from cancer patients), given the
limited immunological tolerance exhibited toward oncofetal
antigens in general. At the very least, our studies suggest that
immune responses against L523S, at the humoral level, are not
incompatible with life. We did not address the possibility that
some of the negative samples in this analysis actually comprised
immune complexes with L523S antigen, thus rendering the
antibody response less detectable, but this is a distinct possibility
given the high rate of L523S antigen positivity in tumour samples,
coupled with the likely presence of cellular antigens from necrotic
tumours within the pleural exudates.
Some studies have shown that humoral and cellular responses to
tumour-associated antigen are correlated with each other (Jager
et al, 1998). However, we are also well aware that patients who had
humoral responses to self-antigens such as L523S went on to have
progressive diseases, suggesting that perhaps an enhancement of
cellular immunity, as mediated by cytotoxic T-cell responses, is
more important to resolve the tumour burden. Studies of L523S
immunogenicity using in vitro human T-cell priming are currently
underway, and in vivo immunogenicity studies are also being
carried out to measure specific cellular and humoral responses
against L523S by vaccination of mice. We are fortunate that the
mouse homologue of L523S is highly conserved relative to the
cognate human sequence, so that immunisation studies in the
mouse are likely to be relevant to the issue of vaccine safety. It is
interesting to note that L523S prevalence is not restricted to lung
cancer, and that L523S was also found to be overexpressed in
pancreatic cancers (Mueller-Pillasch et al, 1997). Thus, the
therapeutic range of L523S may extend to other cancer types.
It is intriguing that L523S, as an oncofetal RNA-binding protein,
is re-expressed in cancerous cells. RNA-binding proteins play
important roles in the post-transcriptional regulation of gene
expression and are known for controlling the localisation, stability,
and translation of mRNA, particularly during early stages of
embryogenesis. Post-transcriptional regulation of gene expression
offers an advantage for genes whose expression is controlled in
according to a temporal or spatial program (Siomi and Dreyfuss,
1997). Although many studies on RNA-binding proteins have
focused on genes involved in development and differentiation
(Oostra, 2002; Reijo et al, 1995), less is known about their roles in
tumourigenesis. Recent studies revealed that multiple embryonic
RNA-binding proteins are overexpressed in several different
cancer types (Mueller-Pillasch et al, 1997; Wang et al, 2000). It is
possible that expression of L523S is necessary for maintenance of
the transformed state, which can potentially be determined by gene
knockout studies such as those performed by RNA interference
(RNAi). If it is indeed shown to be essential, its value as an
antitumour target could be enhanced, since immunological escape
variants might be less likely to develop. In addition, it could
become a preferred target for small molecule development.
p62 Protein, a homologue of L523S with 80% overall sequence
similarity, was found to be an immunogenic autoantigen in human
liver cancers (Zhang et al, 1999). In contrast to L523S, the p62 gene
is expressed in a variety of normal tissues including kidney,
stomach, pancreas, and liver when its mRNA expression is
measured against LSCC (data not shown). However, it is likely
that p62 expression in liver cancers is much higher and more
prevalent. The lower molecular weight protein detected in kidney
and placenta could be to L523S antibody crossreactivity with the
p62 protein (Figure 3), although recent data have shown
autoantibodies from patients have minimal crossreactivity between
L523S and p62 (Zhang et al, 2001). L523S and p62 were also
discovered independently as insulin-like growth factor II mRNA-
binding proteins, known as IMP-3 and IMP-2, respectively
(Nielsen et al, 1999). It will be important to determine if
overexpression of L523S or p62 in cancer cells plays any role in
regulation of transcripts from insulin-like growth factor II or other
growth-related genes. In conclusion, our studies indicate that
L523S may be a valuable addition to the repertoire of cancer-
specific targets for the development of new immunotherapeutic
and perhaps other therapeutic approaches.
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